BIOMAT Database Logo BIOMAT Database Logo

[Maternal glucose tolerance along pregnancy (author's transl)]. 1982

M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner

The development of the foetal and placental unit induces large changes in maternal glucose tolerance along pregnancy. Oestrogen-induced hyperinsulinism is responsible for facilitated anabolism which take place during the first part of pregnancy. Accelerated catabolism occurring during the second part is due to the direct action of placental hormones, mainly of human placental lactogen. The latter is responsible for diminution of peripheral insulin activity. Hyperinsulinism, which is very important at this stage, facilitates an intense and rapid anabolism, mainly in the liver from where nutriments can be easily removed. Glucose and amino-acid uptake by placental and foetus are greatly increased by all these changes.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D010928 Placental Lactogen A polypeptide hormone of approximately 25 kDa that is produced by the SYNCYTIOTROPHOBLASTS of the PLACENTA, also known as chorionic somatomammotropin. It has both GROWTH HORMONE and PROLACTIN activities on growth, lactation, and luteal steroid production. In women, placental lactogen secretion begins soon after implantation and increases to 1 g or more a day in late pregnancy. Placental lactogen is also an insulin antagonist. Choriomammotropin,Chorionic Somatomammotropin, Human,Human Placental Lactogen,Lactogen Hormone, Placental,Mammotropic Hormone, Placental,Somatomammotropin, Chorionic,Choriomammotrophin,HCS (Human Chorionic Somatomammotropin),HPL (Human Placental Lactogen),PAPP-D,Placental Luteotropin,Pregnancy-Associated Plasma Protein D,Chorionic Somatomammotropin,Human Chorionic Somatomammotropin,Lactogen, Placental,Luteotropin, Placental,Placental Lactogen, Human,Placental Mammotropic Hormone,Pregnancy Associated Plasma Protein D
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011262 Pregnancy Trimester, Second The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation. Midtrimester,Pregnancy, Second Trimester,Trimester, Second,Midtrimesters,Pregnancies, Second Trimester,Pregnancy Trimesters, Second,Second Pregnancy Trimester,Second Pregnancy Trimesters,Second Trimester,Second Trimester Pregnancies,Second Trimester Pregnancy,Second Trimesters,Trimesters, Second
D011263 Pregnancy Trimester, Third The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation. Pregnancy, Third Trimester,Trimester, Third,Last Trimester,Last Trimesters,Pregnancies, Third Trimester,Pregnancy Trimesters, Third,Third Pregnancy Trimester,Third Pregnancy Trimesters,Third Trimester,Third Trimester Pregnancies,Third Trimester Pregnancy,Third Trimesters,Trimester, Last,Trimesters, Last,Trimesters, Third
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005260 Female Females
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral

Related Publications

M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
[The oral glucose tolerance test (author's transl)].
January 1980, Annales de medecine interne,
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
[Glucose tolerance and muscular efficiency (author's transl)].
March 1979, Medizinische Klinik,
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
[Glucose tolerance and neurogenic muscular atrophies (author's transl)].
June 1978, Medizinische Klinik,
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
Maternal BMI, glucose tolerance, and adverse pregnancy outcomes.
July 2012, American journal of obstetrics and gynecology,
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
[Comparison of oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT) for estimation of a latent disorder of glucose tolerance during pregnancy (author's transl)].
September 1978, Ceskoslovenska gynekologie,
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
[Oral glucose tolerance test and blood eosinophils (author's transl)].
April 1982, Annales pharmaceutiques francaises,
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
[Massive obesity with disturbance of glucose tolerance (author's transl)].
October 1979, Deutsche medizinische Wochenschrift (1946),
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
[Flat curves of oral glucose tolerance tests (author's transl)].
April 1980, La Nouvelle presse medicale,
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
Maternal glucose tolerance during pregnancy with excessive size infants.
February 1980, Obstetrics and gynecology,
M Pinget, and R Gandar, and C Jacques, and M Zaehringer, and F Truchetet, and M Dorner
Maternal glucose tolerance in pregnancy affects fetal insulin sensitivity.
September 2010, Diabetes care,
Copied contents to your clipboard!